醋酸依替巴肽用途
Eptifibatide, also co-promoted by Schering-Plough/Essex, is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
1、产品物理参数：
2、醋酸依替巴肽物理化学性质
|
密度
|
1.6±0.1 g/cm3
|
|
熔点
|
92-98 °C
|
|
分子式
|
C35H49N11O9S2
|
|
分子量
|
831.962
|
|
精*确质量
|
831.315613
|
|
PSA
|
374.49000
|
|
LogP
|
-4.84
|
|
折射率
|
1.735
|
|
分子结构
|
1、摩尔折射率：208.03
2、摩尔体积（cm3/mol）：518.4
3、等张比容（90.2K）：1530.5
4、表面张力（dyne/cm）：75.9
5、介电常数：无可用的
6、极化率（10-24cm3）：82.47
7、单一同位素质量：831.315612 Da
8、标称质量：831 Da
9、平均质量：831.9619 Da
|
|
计算化学
|
1.疏水参数计算参考值（XlogP）:-2.4
2.氢键供体数量:10
3.氢键受体数量:12
4.可旋转化学键数量:10
5.互变异构体数量:1000
6.拓扑分子极性表面积377
7.重原子数量:57
8.表面电荷:0
9.复杂度:1520
10.同位素原子数量:0
11.确定原子立构中心数量:0
12.不确定原子立构中心数量:5
13.确定化学键立构中心数量:0
14.不确定化学键立构中心数量:0
15.共价键单元数量:1
|
3、醋酸依替巴肽英文别名
|
n6-(aminoiminomethyl)-n2-(3-mercapto-1-oxopropyl-l-lysylglycyl-l-a-aspartyl-l-tryptophyl-l-prolyl-l-cysteinamide
|
|
7H-Pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-[4-[(aminoiminomethyl)amino]butyl]docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-
|
|
Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridge:1-7)
|
|
EFTIFIBATIDE
|
|
MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2
|
|
MFCD05662245
|
|
[11-(4-Carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
|
|
Mpr-Harg-Gly-Asp-Trp-Pro-Cys-NH2,( Disulfide Bridg on Mpr and Cys)
|
|
Eptifitide
|
|
INTEGRELIN
|
|
Eptifibatide Acetate
|
|
7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosine-17-acetic acid, 3-(aminocarbonyl)-11-[4-[(diaminomethylene)amino]butyl]docosahydro-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxo-
|
